Antiinflammatory properties of a peptide derived from interleukin-4
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Antiinflammatory properties of a peptide derived from interleukin-4. / Klementiev, Boris; Enevoldsen, Maj N; Li, Shizhong; Carlsson, Robert; Liu, Yawei; Navikas, Shohreh; Bock, Elisabeth; Berezin, Vladimir.
In: Cytokine, Vol. 64, No. 1, 10.2013, p. 112-21.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antiinflammatory properties of a peptide derived from interleukin-4
AU - Klementiev, Boris
AU - Enevoldsen, Maj N
AU - Li, Shizhong
AU - Carlsson, Robert
AU - Liu, Yawei
AU - Navikas, Shohreh
AU - Bock, Elisabeth
AU - Berezin, Vladimir
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/10
Y1 - 2013/10
N2 - Interleukin-4 (IL-4) is a potent antiinflammatory cytokine. However its use in the clinic is hampered by side effects. We here describe the identification of a novel synthetic peptide, termed Ph8, derived from α-helix C of IL-4, which interacts with IL-4 receptor α (IL-4Rα). Employing various cultured genetically engineered cell lines and primary lymphocytes, surface plasmon resonance, qPCR, ELISA and immunoblotting techniques we found that Ph8 bound IL-4Rα and mimicked the anti-inflammatory effects of IL-4 by inhibiting TNF-α production by macrophages in vitro. It induced phosphorylation of STAT6 65kD but inhibited phosphorylation of STAT6 110 kD induced by IL-4 in a B-cell line that expressed the type I receptor. It also inhibited the IL-4-stimulated expression of a STAT6-inducible reporter gene in cells that expressed the type II receptor. Ph8 inhibited the proliferation of Th1/2 cells and downregulated the production of IFN-γ in stimulated Th1 cells. Moreover, Ph8 did not induce any shift in Th1/Th2 profile. This is a favorable effect and it is indicating that Ph8 could block general T cell activation and inflammatory responses without further inducing the side effects generally associated with IL-4 signaling. These data collectively show that Ph8 is only a partial agonist of IL-4 mimicking its desirable properties. In agreement, Ph8 treatment of rats with collagen-induced arthritis, a Th1- and antibody- mediated disease of joint, delayed the manifestation of chronic inflammation and reduced acute inflammation in carrageenan-induced edema. Our findings indicate that Ph8 is a promising potential drug candidate for the treatment of inflammatory diseases.
AB - Interleukin-4 (IL-4) is a potent antiinflammatory cytokine. However its use in the clinic is hampered by side effects. We here describe the identification of a novel synthetic peptide, termed Ph8, derived from α-helix C of IL-4, which interacts with IL-4 receptor α (IL-4Rα). Employing various cultured genetically engineered cell lines and primary lymphocytes, surface plasmon resonance, qPCR, ELISA and immunoblotting techniques we found that Ph8 bound IL-4Rα and mimicked the anti-inflammatory effects of IL-4 by inhibiting TNF-α production by macrophages in vitro. It induced phosphorylation of STAT6 65kD but inhibited phosphorylation of STAT6 110 kD induced by IL-4 in a B-cell line that expressed the type I receptor. It also inhibited the IL-4-stimulated expression of a STAT6-inducible reporter gene in cells that expressed the type II receptor. Ph8 inhibited the proliferation of Th1/2 cells and downregulated the production of IFN-γ in stimulated Th1 cells. Moreover, Ph8 did not induce any shift in Th1/Th2 profile. This is a favorable effect and it is indicating that Ph8 could block general T cell activation and inflammatory responses without further inducing the side effects generally associated with IL-4 signaling. These data collectively show that Ph8 is only a partial agonist of IL-4 mimicking its desirable properties. In agreement, Ph8 treatment of rats with collagen-induced arthritis, a Th1- and antibody- mediated disease of joint, delayed the manifestation of chronic inflammation and reduced acute inflammation in carrageenan-induced edema. Our findings indicate that Ph8 is a promising potential drug candidate for the treatment of inflammatory diseases.
KW - Animals
KW - Anti-Inflammatory Agents, Non-Steroidal
KW - Arthritis, Experimental
KW - Cell Proliferation
KW - Edema
KW - HEK293 Cells
KW - Humans
KW - Interferon-gamma
KW - Interleukin-4
KW - Interleukin-4 Receptor alpha Subunit
KW - Lymphocyte Activation
KW - Macrophage Activation
KW - Macrophages
KW - Male
KW - Mice
KW - Mice, Inbred C57BL
KW - Peptide Fragments
KW - Phosphorylation
KW - Protein Binding
KW - Rats
KW - Rats, Wistar
KW - STAT6 Transcription Factor
KW - Th1 Cells
KW - Tumor Necrosis Factor-alpha
U2 - 10.1016/j.cyto.2013.07.016
DO - 10.1016/j.cyto.2013.07.016
M3 - Journal article
C2 - 23972727
VL - 64
SP - 112
EP - 121
JO - Cytokine
JF - Cytokine
SN - 1043-4666
IS - 1
ER -
ID: 108143264